KSP 0243
Alternative Names: KSP-0243Latest Information Update: 09 Jun 2023
At a glance
- Originator Kissei Pharmaceutical
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Ulcerative colitis
Most Recent Events
- 27 Apr 2023 Phase-II clinical trials in Ulcerative colitis (In Adults, In the elderly) in Japan (PO, Tablet) (NCT05831670)
- 26 Apr 2023 Kissei Pharmaceutical plans a phase IIa trial for Ulcerative colitis (In adults, In the elderly) (PO) (NCT05831670)